1naresh
Array
(
[urn:ac.highwire.org:guest:identity] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:identity
[type] => guest
[service-id] => ajnr-ac.highwire.org
[access-type] => Controlled
[privilege] => Array
(
[urn:ac.highwire.org:guest:privilege] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:privilege
[type] => privilege-set
[privilege-set] => GUEST
)
)
[credentials] => Array
(
[method] => guest
)
)
)
1nareshArray
(
[urn:ac.highwire.org:guest:identity] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:identity
[type] => guest
[service-id] => ajnr-ac.highwire.org
[access-type] => Controlled
[privilege] => Array
(
[urn:ac.highwire.org:guest:privilege] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:privilege
[type] => privilege-set
[privilege-set] => GUEST
)
)
[credentials] => Array
(
[method] => guest
)
)
)
Table 2: ADC values of the newly developed or increased enhancing portion and deep cervical muscles
Value (Mean ± SD) P Valuea Recurrent Tumor Posttreatment Changes Newly detected or increased enhancing lesion ADC1000 (10−3 mm2/s) 1.205 ± 0.244 1.649 ± 0.319 <.001 ADC2000 (10−3 mm2/s) 0.878 ± 0.153 0.940 ± 0.235 .365 ADCratio (%) 73.5 ± 7.2 56.9 ± 8.8 <.001 Deep cervical muscles ADC1000 (10−3 mm2/s) 1.338 ± 0.103 1.301 ± 0.133 .371 ADC2000 (10−3 mm2/s) 0.722 ± 0.128 0.724 ± 0.157 .967 ADCratio (%) 53.9 ± 8.1 55.2 ± 7.8 .643
↵a Calculated using the 2-tailed independent Student t test.